PDF(1256 KB)
经皮下特异性免疫治疗的支气管哮喘和/或过敏性鼻炎患儿全身不良反应观察及危险因素分析
廖旺, 陈亮, 白珺
中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (11) : 1204-1208.
PDF(1256 KB)
PDF(1256 KB)
经皮下特异性免疫治疗的支气管哮喘和/或过敏性鼻炎患儿全身不良反应观察及危险因素分析
Systemic reactions to subcutaneous immunotherapy for bronchial asthma and/or allergic rhinitis in children and their risk factors
目的 分析皮下特异性免疫治疗（SCIT）治疗儿童支气管哮喘和/或变应性鼻炎的全身不良反应（SR）的发生情况及危险因素。方法 回顾性分析该院儿科收治的支气管哮喘和/或变应性鼻炎患儿198例为研究对象。根据所有患儿SCIT过程中SR和局部不良反应（LR）的发生情况，分为SR组（n=31）及对照组（未发生SR及LR的患儿，n=142），采用logistic多因素回归分析对发生SR的危险因素进行分析。结果 在对198例患儿的8 157次SCIT注射中，共有25（12.6%）例患儿发生31例次（0.38%）SR，其中Ⅰ级SR 18例次（58%），Ⅱ级SR 10例次（32%），Ⅲ级SR 3例次（10%），无Ⅳ级SR。多因素logistic回归分析显示同时合并食物及吸入过敏原的多重过敏、尘螨sIgE 6级、总IgE 6级、既往LR发生史是SR的独立危险因素（P < 0.05）。结论 SCIT治疗哮喘和/或过敏性鼻炎的SR发生率低，安全性良好。对同时合并食物及吸入过敏原的多重过敏、高敏状态（尘螨sIgE 6级、总IgE 6级）、既往局部不良反应发生史者需警惕SR发生。
Objective To investigate the incidence of systemic reactions (SR) to subcutaneous immunotherapy (SCIT) for bronchial asthma and/or allergic rhinitis in children and their risk factors. Methods A retrospective analysis was performed on 198 children with bronchial and/or allergic rhinitis. According to the presence or absence of SR and local reactions (LR) during SCIT, the patients were divided into two groups:SR (with SR and LR, n=31) and control (without SR or LR, n=142). A multivariate logistic regression analysis was used to determine the risk factors associated with SR. Results Among the 198 patients who received 8 157 injections of SCIT, 25 (12.6%) experienced SR (31 times, 0.38%), including grade I SR (18 times, 58%), grade II SR (10 times, 32%), grade III SR (3 times, 10%), and no grade IV SR. The multivariate logistic regression analysis showed that multiple sensitization with both food and inhaled allergens, specific IgE to dust mites (grade 6), total IgE (grade 6), and a history of LR were independent risk factors for SR (P < 0.05). Conclusions SCIT is a safe treatment for bronchial asthma and/or allergic rhinitis in children, with a low incidence of SR. Children with multiple sensitization with both food and inhaled allergens, a hypersensitive state (specific IgE to dust mites, grade 6; total IgE, grade 6), and a history of LR have an increased risk of SR to SCIT.
支气管哮喘 / 过敏性鼻炎 / 皮下特异性免疫治疗 / 全身不良反应 / 儿童
Bronchial asthma / Allergic rhinitis / Subcutaneous immunotherapy / Systemic reaction / Child
[1] 向莉, 赵京, 鲍一笑, 等. 儿童气道过敏性疾病螨特异性免疫治疗专家共识[J]. 中华实用儿科临床杂志, 2018, 33(16):1215-1223.
[2] Tang RB. House dust mite-specific immunotherapy alters the natural course of atopic march[J]. J Chin Med Assoc, 2020, 83(2):109-112.
[3] Jutel M, Brüggenjürgen B, Richter H, et al. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma[J]. Allergy, 2020, 75(8):2046-2054.
[4] Lim CE, Sison CP, Ponda P. Comparison of pediatric and adult systemic reactions to subcutaneous immunotherapy[J]. J Allergy Clin Immunol Pract, 2017, 5(5):1241-1247.e2.
[5] 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童支气管哮喘诊断与防治指南(2016年版)[J]. 中华儿科杂志, 2016, 54(3):167-181.
[6] 中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 儿童过敏性鼻炎诊疗——临床实践指南[J]. 中国实用儿科杂志, 2019, 34(3):169-175.
[7] Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy[J]. Allergy, 2006, 61(Suppl 82):1-20.
[8] Tophof MA, Hermanns A, Adelt T, et al. Side effects during subcutaneous immunotherapy in children with allergic diseases[J]. Pediatr Allergy Immunol, 2018, 29(3):267-274.
[9] 冯仙, 刘琢扶, 顾泓, 等. 变应性鼻炎患者皮下特异性免疫治疗的全身不良反应情况分析[J]. 中国眼耳鼻喉科杂志, 2019, 19(4):262-266.
[10] Liu JL, Ning WX, Li SX, et al. The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East China[J]. Allergol Immunopathol (Madr), 2017, 45(6):541-548.
[11] Bernstein DI, Epstein TEG. Safety of allergen immunotherapy in North America from 2008-2017:lessons learned from the ACAAI/AAAAI national surveillance study of adverse reactions to allergen immunotherapy[J]. Allergy Asthma Proc, 2020, 41(2):108-111.
[12] van de Veen W, Wirz OF, Globinska A, et al. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy[J]. Curr Opin Immunol, 2017, 48:74-81.
[13] 中国过敏性鼻炎研究协作组. 过敏性鼻炎皮下免疫治疗的安全性[J]. 中国耳鼻咽喉头颈外科, 2017, 24(1):1-14.
[14] Dong X, Huang N, Li W, et al. Systemic reactions to dust mite subcutaneous immunotherapy:a 3-year follow-up study[J]. Allergy Asthma Immunol Res, 2016, 8(5):421-427.
[15] Nacaroglu HT, Erdem SB, Sumer O, et al. Local and systemic reactions to subcutaneous allergen immunotherapy:ten years' experience in a pediatric clinic[J]. Ann Allergy Asthma Immunol, 2016, 116(4):349-353.
[16] Sani S, Gupta R, Fonacier L, et al. Risk stratification of systemic reactions to subcutaneous immunotherapy:a retrospective study[J]. Allergy Asthma Proc, 2019, 40(5):338-342.
[17] Wahn U, Matricardi PM, Bieber T, et al. Food allergy in EAACI journals (2016)[J]. Pediatr Allergy Immunol, 2017, 28(8):825-830.
[18] Kartal O, Gulec M, Caliskaner Z, et al. Safety of subcutaneous immunotherapy with inhalant allergen extracts:a single-center 30-year experience from Turkey[J]. Immunopharmacol Immunotoxicol, 2015, 37(3):280-286.
